Shaping Drug Development by Starting with the Disease with Roche's Sylke Poehling, Ph.D.

We love to hear from our listeners. Send us a message. In episode 137 of Cell & Gene: The Podcast, Host Erin Harris talks with Sylke Poehling, Ph.D., SVP and Global Head: Therapeutic Modalities, pRED; Roche Gene Therapy Center of Excellence about how the company selects the optimal modality by starting with disease biology. Dr. Poehling explains how an integrated Center of Excellence brings together discovery, safety, manufacturing, and development expertise to reduce technical risk and accelerate progress. She outlines where AI is already creating value versus where caution is warranted. She also explains why genomic medicines will become mainstream when, for common diseases, physicians can offer them as routine options and patients can choose them with confidence.  Subscribe to the podcast! Apple  |  Spotify |  YouTube Visit my website: Cell & Gene Connect with me on LinkedIn